Sold by: Next Move Strategy Consulting
Deployed on AWS
Access market sizing, forecasts, segmentation, regional analysis, competitive intelligence, and company profiles for the global Ovarian Cancer Drug Market, valued at USD 5.21 billion in 2025 and projected to reach USD 8.58 billion by 2030 at a CAGR of 10.50%.
Overview
Ovarian Cancer Drug Market Data Product Overview
The Ovarian Cancer Drug Market data product covers market sizing, historical and forecast analysis, market segmentation, regional and country-level insights, competitive analysis, key players, strategic developments, and investment opportunities. The market was valued at USD 4.71 billion in 2024 and is estimated at USD 5.21 billion in 2025, with revenue projected to reach USD 8.58 billion by 2030 at a CAGR of 10.50% from 2025 to 2030. The study analyzes cancer type, treatment type, route of administration, distribution channels, end-users, and regional markets, with coverage across 28 countries. The research combines primary interviews with industry experts and secondary research from proprietary databases and industry sources, with market findings presented on an aggregated basis.
Use Cases
-
Market entry sizing: Assess the market opportunity from USD 5.21 billion in 2025 to USD 8.58 billion by 2030, supported by analysis across 28 countries and major geographic regions.
-
Therapy portfolio evaluation: Compare targeted therapy, chemotherapy, hormone therapy, and immunotherapy, including subcategories such as PARP inhibitors, angiogenesis inhibitors, PD-L1 inhibitors, platinum-based agents, taxanes, and monoclonal antibodies.
-
Competitive benchmarking: Evaluate 10 profiled companies across the ovarian cancer drug landscape, with market-share analysis available for 10 companies and strategic developments covering approvals, partnerships, acquisitions, and pipeline activity.
-
Commercial and channel strategy: Assess opportunities by oral, intravenous, intraperitoneal, and subcutaneous/intramuscular administration routes, as well as hospital, retail, and online pharmacy channels and hospital, cancer treatment center, specialty clinic, and home-care end-users.
Metadata
Update Frequency: One-time syndicated product
Data Source(s): Primary interviews + secondary research (proprietary databases, industry journals)
Original Publisher of data: Next Move Strategy Consulting
Geographic coverage: 28 countries across North America, Europe, Asia-Pacific, and Rest of the World, including Latin America, Middle East, and Africa, with country-level analysis
Time period coverage: 2024–2030
Is historical data "point-in-time": Historical figures are point-in-time market estimates as of publication; forecast years are projections
Data Set(s) Format(s): PDF / Excel
Raw or scraped data: No — syndicated analyst research
Key Fields: Market size, CAGR, historical and forecast values, cancer type, treatment type, route of administration, distribution channels, end-users, regional and country analysis, company profiles, market share, competitive developments, growth drivers, restraints, and investment opportunities
Number of companies/brands covered: 10
Key Data Points
- USD 4.71 billion — global Ovarian Cancer Drug Market size in 2024.
- USD 5.21 billion — estimated global market size in 2025.
- USD 8.58 billion — projected market revenue in 2030.
- 10.50% — CAGR projected from 2025 to 2030.
- 28 countries — geographic coverage, with 10 companies profiled.
Additional Information Company Fact Sheet: nextmsc.com
Pricing Information
Customized purchase options are available for this report. Subscribers should inquire for applicable licensing and purchase options. Actual pricing is provided through the AWS Data Exchange offer.
Regulatory and Compliance Information
This report is built from aggregated, publicly available, and licensed secondary sources plus expert interviews conducted on an aggregated basis. It contains no individually identifiable personal data.
Subscription Verification
AWS Data Exchange requires subscription verification on all public offers (subscribers confirm they're not in a restricted country or a covered party).
Need Help?
For questions about this product, contact info@nextmsc.com .
About Your Company
Next Move Strategy Consulting (NextMSC) is a Boston-based market research and management consulting firm producing syndicated and custom research across healthcare and life sciences and other sectors, combining primary expert interviews with secondary research from proprietary databases. Its healthcare research covers pharmaceuticals, oncology, diagnostics, therapies, and related healthcare markets. Learn more at nextmsc.com
Highlights
- The global Ovarian Cancer Drug Market was valued at USD 4.71 billion in 2024 and is estimated to reach USD 5.21 billion in 2025. The market is projected to reach USD 8.58 billion by 2030, reflecting a 10.50% CAGR from 2025 to 2030.
- The study provides detailed segmentation across 6 major dimensions: cancer type, treatment type, route of administration, distribution channels, end-users, and region. Coverage includes targeted therapy, chemotherapy, hormone therapy, immunotherapy, oral and intravenous administration, and hospital, retail, and online pharmacy channels.
- The report covers 28 countries and profiles 10 companies, with market-share analysis available for 10 companies. It evaluates strategic developments including regulatory approvals, clinical progress, partnerships, acquisitions, emerging therapies, personalized medicine, home-based treatments, and opportunities for novel drug development.
Details
Categories
Delivery method
Deployed on AWS
New
Introducing multi-product solutions
You can now purchase comprehensive solutions tailored to use cases and industries.
Features and programs
Financing for AWS Marketplace purchases
AWS Marketplace now accepts line of credit payments through the PNC Vendor Finance program. This program is available to select AWS customers in the US, excluding NV, NC, ND, TN, & VT.
Pricing
Custom pricing options
Pricing is based on your specific requirements and eligibility. Sign in to view any offers that have been extended to you.
Legal
Content disclaimer
Vendors are responsible for their product descriptions and other product content. AWS does not warrant that vendors' product descriptions or other product content are accurate, complete, reliable, current, or error-free.
Delivery details
AWS Data Exchange (ADX)
AWS Data Exchange is a service that helps AWS easily share and manage data entitlements from other organizations at scale.
Additional details
You will receive access to the following data sets.
Data set name | Type | Historical revisions | Future revisions | Sensitive information | Data dictionaries | Data samples |
|---|---|---|---|---|---|---|
NMSC_MarketResearch | All historical revisions | All future revisions | Not included | Not included |
Similar products
Access market sizing, segmentation, competitive analysis, and regional insights for the Lung Cancer Surgery Market, projected to reach USD 6.33 billion by 2030 at a 4.9% CAGR from 2025–2030.
Access market sizing, forecasts, segmentation, regional analysis, competitive intelligence, and company profiles for the global Vascular Dementia (VaD) Drugs Market, valued at USD 2.9 billion in 2025 and projected to reach USD 3.6 billion by 2030 at a CAGR of 4.3%.
Get structured market intelligence on cancer therapeutics, including therapy, cancer type, key drug, end-user, regional segmentation and competitive activity. The market is projected to reach USD 326.05 billion by 2034, with a 9.4% CAGR stated for 2025–2030.
The projected size of the Global Cancer Gene Therapy Market is anticipated to reach $558 billion by 2030, exhibiting a remarkable Compound Annual Growth Rate (CAGR) of 33% from 2024 to 2030. In light of this prevalent health challenge, the global cancer gene therapy market is experiencing robust growth.